Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Solid subtype, micropapillary subtype, vascular involvement, pleural involvement and low
differentiation are high risk factors of post-operative recurrence for early-stage lung
adenocarcinoma patients. The purpose of this clinical trial is to determine whether the
widely used adjuvant chemotherapy strategy cisplatin/ pemetrexed is more effective than no
further treatment for Stage pI lung adenocarcinoma patients with high post-operative
recurrence risk - in terms of no dose related toxicities, premature treatment withdrawal or
death.